Clinical Trial Detail

NCT ID NCT03715933
Title Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Inhibrx, Inc.
Indications

gastric adenocarcinoma

malignant pleural mesothelioma

colorectal adenocarcinoma

sarcoma

Advanced Solid Tumor

Therapies

INBRX-109

Age Groups: adult senior

No variant requirements are available.